Hydroxychloroquine Prophylaxis against Coronavirus Disease-19: Practice Outcomes among Health-Care Workers

{ 'institution': [{'name': 'medRxiv'}], 'indexed': {'date-parts': [[2022, 3, 31]], 'date-time': '2022-03-31T19:11:56Z', 'timestamp': 1648753916737}, 'posted': {'date-parts': [[2021, 8, 4]]}, 'group-title': 'Infectious Diseases (except HIV/AIDS)', 'reference-count': 34, 'publisher': 'Cold Spring Harbor Laboratory', 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'accepted': {'date-parts': [[2021, 8, 4]]}, 'abstract': '<jats:title>ABSTRACT</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>Severe ' 'acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a rapidly emerging virus responsible ' 'for the ongoing Covid-19 pandemic with no known effective prophylaxis. We investigated ' 'whether hydroxychloroquine(HCQ) could prevent SARS CoV-2 in healthcare workers(HCW) at ' 'high-risk of ' 'exposure.</jats:p></jats:sec><jats:sec><jats:title>Method</jats:title><jats:p>This voluntary ' 'observational study for the prevention and treatment of COVID-19 was conducted at a tertiary ' 'care center, from 12<jats:sup>th</jats:sup> June to 12th October 2020(total 16 weeks). All ' 'consented asymptomatic HCW’s of CIMS hospital were administered 400 mg HCQ twice a day on day ' 'one followed by 400 mg once weekly to be taken with meals up to 16 weeks. Data collected ' 'included OPD registration, risk assessment, medical and family history (related to COVID), ' 'physical examination and vitals, pulse oximetry, ECG (pre and post HCQ), drug adherence, side ' 'effects, adverse drug ' 'reactions.</jats:p></jats:sec><jats:sec><jats:title>Result</jats:title><jats:p>The study ' 'enrolled 927 full-time, hospital-based HCWs ((including doctors, nurses, paramedical, lab ' 'technicians, sanitary workers and others), of whom 731(78.85%) initially started HCQ while ' '196 (21.14%) did not volunteer. The median age and weight of the study population was 27.5 ' 'years and 69.5 kg respectively. No major associated co-morbidities were present in these ' 'HCW’s. There was an increased trend towards non adherence to HCQ with each proceeding week ' 'more so after week 11. Of the 731 HCW’s taking HCQ a total of 167(22.8%) tested COVID ' 'positive at different intervals of time as against 30 HCW (15.3%) out of 196 not taking HCQ. ' 'The rate of COVID-19 positive was statistically significantly higher in the HCW’s taking HCQ ' '(p=0.0220; 95% CI: 1.14% to 12.94%), as compared to those not on HCQ. Thus HCQ was not ' 'prophylactically effective against COVID 19 infection. No participants in this study ' 'experienced grade 3 or 4 adverse events. No significant difference in the median of ECG ' 'changes in QTc between pre and post HCQ administration of 46 HCW’s was ' 'observed.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>This ' 'clinical study did not detect a reduction in SARS CoV-2 transmission with prophylactic ' 'administration of 400 mg/HCQ in HCW’s. All participants who did contract SARSCoV-2 were ' 'either asymptomatic or had mild disease courses with full recoveries. All adverse events were ' 'self-limiting and no serious cardiovascular events were reported with use of HCQ. In the ' 'absence of robust data, it seems premature to recommend HCQ as a prophylactic panacea for ' 'COVID-19.</jats:p></jats:sec>', 'DOI': '10.1101/2021.08.02.21260750', 'type': 'posted-content', 'created': {'date-parts': [[2021, 8, 4]], 'date-time': '2021-08-04T17:20:40Z', 'timestamp': 1628097640000}, 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'Hydroxychloroquine Prophylaxis against Coronavirus Disease-19: Practice Outcomes among ' 'Health-Care Workers', 'prefix': '10.1101', 'author': [ {'given': 'Parloop', 'family': 'Bhatt', 'sequence': 'first', 'affiliation': []}, {'given': 'Vishva', 'family': 'Patel', 'sequence': 'additional', 'affiliation': []}, {'given': 'Prachi', 'family': 'Shah', 'sequence': 'additional', 'affiliation': []}, {'given': 'Keyur', 'family': 'Parikh', 'sequence': 'additional', 'affiliation': []}], 'member': '246', 'reference': [ { 'key': '2021080605200974000_2021.08.02.21260750v1.1', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMoa2001316'}, { 'key': '2021080605200974000_2021.08.02.21260750v1.2', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/S1473-3099(20)30287-5'}, { 'key': '2021080605200974000_2021.08.02.21260750v1.3', 'unstructured': 'World Health Organization. Report of the WHO-China Joint Mission on ' 'Coronavirus Disease 2019 (COVID-19). February 2020 ' '(https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf).'}, { 'key': '2021080605200974000_2021.08.02.21260750v1.4', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.ijid.2020.01.050'}, { 'key': '2021080605200974000_2021.08.02.21260750v1.5', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMoa2001017'}, { 'key': '2021080605200974000_2021.08.02.21260750v1.6', 'unstructured': 'World Health Organization. Strengthening preparedness for COVID-19 in ' 'cities and urban settings. April 2020 ' '(https://www.who.int/publications-detail/strengthening-preparedness-for-covid-19-in-cities-and-urban-settings).'}, { 'key': '2021080605200974000_2021.08.02.21260750v1.7', 'doi-asserted-by': 'crossref', 'first-page': '488', 'DOI': '10.1016/S2214-109X(20)30074-7', 'article-title': 'Centre for the Mathematical Modelling of Infectious Diseases COVID-19 ' 'Working Group; Sebastian Funk, Rosalind M Eggo. Feasibility of ' 'controlling COVID-19 outbreaks by isolation of cases and contacts', 'volume': '8', 'year': '2020', 'journal-title': 'Lancet Glob Health'}, { 'key': '2021080605200974000_2021.08.02.21260750v1.8', 'unstructured': 'Modes of Transmission of Virus Causing Covid-19: Implications for IPC ' 'Precaution Recommendations. Available from: ' 'https://www.who.int/newsroom/commentaries/detail/modes-of-transmission-of-virus-causing-Covid-19-implications-for-ipc-precaution-recommendations. ' '[Last accessed on 2020 Apr 23].'}, { 'key': '2021080605200974000_2021.08.02.21260750v1.9', 'unstructured': 'Chemoprophylaxis of SARS CoV 2 Infection (Covid 19) in Exposed ' 'Healthcare Workers Full Text View ClinicalTrials. gov;2020. Available ' 'from: https://clinicaltrials.gov/ct2/show/NCT04328285. [Last accessed on ' '2020 Apr 23].'}, { 'key': '2021080605200974000_2021.08.02.21260750v1.10', 'unstructured': 'The PATCH Trial (Prevention and Treatment of Covid 19 with ' 'Hydroxychloroquine) Full Text View ClinicalTrials.gov; 2020. Available ' 'from: https://clinicaltrials.gov/ct2/show/NCT04329923. [Last accessed on ' '2020 Apr 23].'}, { 'key': '2021080605200974000_2021.08.02.21260750v1.11', 'unstructured': 'National Taskforce for COVID-19. Advisory on the use of ' 'hydroxy-chloroquine as prophylaxis for SARS-CoV-2 infection. 2020. ' 'https://www.mohfw.gov.in/pdf/AdvisoryontheuseofHydroxychloroquinasprophylaxisforSARSCoV2infection.pdf ' '(accessed March 23, 2020).'}, { 'key': '2021080605200974000_2021.08.02.21260750v1.12', 'unstructured': 'National Taskforce for COVID-19. Revised advisory on the use of ' 'Hydroxychloroquine (HCQ) as prophylaxis for COVID-19 infection (in ' 'supersession of previous advisory dated 23rd March, ' '2020).https://www.mohfw.gov.in/pdf/RevisedadvisoryontheuseofhydroxychloroquineasprophylaxisforSARSCOVID19infection.pdf'}, { 'key': '2021080605200974000_2021.08.02.21260750v1.13', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/art.1780331001'}, { 'key': '2021080605200974000_2021.08.02.21260750v1.14', 'doi-asserted-by': 'publisher', 'DOI': '10.1136/ard.2006.068676'}, { 'key': '2021080605200974000_2021.08.02.21260750v1.15', 'doi-asserted-by': 'publisher', 'DOI': '10.1007/s40261-018-0656-y'}, { 'key': '2021080605200974000_2021.08.02.21260750v1.16', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/rheumatology/41.8.924'}, { 'key': '2021080605200974000_2021.08.02.21260750v1.17', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41584-020-0372-x'}, { 'key': '2021080605200974000_2021.08.02.21260750v1.18', 'doi-asserted-by': 'publisher', 'DOI': '10.20944/preprints202003.0275.v1)'}, { 'key': '2021080605200974000_2021.08.02.21260750v1.19', 'first-page': '1289', 'article-title': 'Emerging prophylaxis strategies against COVID-19: Pulmonary medicine ' 'and critical care jodhpur', 'volume': '90', 'year': '2020', 'journal-title': 'Monaldi Archives for Chest Disease'}, { 'key': '2021080605200974000_2021.08.02.21260750v1.20', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.ijantimicag.2020.105949'}, { 'key': '2021080605200974000_2021.08.02.21260750v1.21', 'first-page': '269', 'article-title': 'Remdesivir and chloroquine effectively inhibit the recently emerged ' 'novel coronavirus (2019-nCoV) in vitro', 'volume': '3', 'year': '2020', 'journal-title': 'Cell Res'}, { 'key': '2021080605200974000_2021.08.02.21260750v1.22', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/S1473-3099(07)70187-1'}, { 'key': '2021080605200974000_2021.08.02.21260750v1.23', 'unstructured': 'FDA / CDER. Plaquenil ® Hydroxychloroquine Sulfate Tablets, Usp ' 'Description. FDA, 2017. http://www.cdc.gov/malaria'}, { 'key': '2021080605200974000_2021.08.02.21260750v1.24', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/cid/ciaa237'}, { 'key': '2021080605200974000_2021.08.02.21260750v1.25', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.antiviral.2015.01.011'}, { 'key': '2021080605200974000_2021.08.02.21260750v1.26', 'unstructured': 'EMA (2020). COVID-19: reminder of the risk of chloroquine and ' 'hydroxychloroquine. Available at: ' 'https://www.ema.europa.eu/en/news/covid-19-reminder-risks-chloroquine-hydroxychloroquine ' '(Accessed May 29, 2020).'}, { 'key': '2021080605200974000_2021.08.02.21260750v1.27', 'doi-asserted-by': 'publisher', 'DOI': '10.3389/fphar.2020.605185'}, { 'key': '2021080605200974000_2021.08.02.21260750v1.28', 'unstructured': 'Clinical trials register website (2020). Available at: ' 'https://www.clinicaltrialsregister.eu/ (Accessed June 15, 2020).'}, { 'key': '2021080605200974000_2021.08.02.21260750v1.29', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.onehlt.2020.100141'}, { 'key': '2021080605200974000_2021.08.02.21260750v1.30', 'doi-asserted-by': 'publisher', 'DOI': '10.1007/s12016-010-8243-x'}, { 'key': '2021080605200974000_2021.08.02.21260750v1.31', 'doi-asserted-by': 'publisher', 'DOI': '10.1007/s00393-020-00785-4'}, { 'key': '2021080605200974000_2021.08.02.21260750v1.32', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.jaad.2020.04.024'}, { 'key': '2021080605200974000_2021.08.02.21260750v1.33', 'doi-asserted-by': 'publisher', 'DOI': '10.1001/jamainternmed.2020.6319'}, { 'key': '2021080605200974000_2021.08.02.21260750v1.34', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/cid/ciaa1571'}], 'container-title': [], 'original-title': [], 'link': [ { 'URL': 'https://syndication.highwire.org/content/doi/10.1101/2021.08.02.21260750', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2021, 8, 6]], 'date-time': '2021-08-06T12:20:57Z', 'timestamp': 1628252457000}, 'score': 1, 'resource': {'primary': {'URL': 'http://medrxiv.org/lookup/doi/10.1101/2021.08.02.21260750'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2021, 8, 4]]}, 'references-count': 34, 'URL': 'http://dx.doi.org/10.1101/2021.08.02.21260750', 'relation': {}, 'published': {'date-parts': [[2021, 8, 4]]}, 'subtype': 'preprint'}